Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Dollar and Under Sleeper Stocks -- Ignore unavailable to you. Want to Upgrade?

To: jeffrey rainey who wrote (7164)	9/2/1998 9:33:00 PM
From: David W. Tucker	Read Replies (1) \| Respond to of 8835

Here is a detailed and informative site on a prospective investment opportunity: NRAG. The site was put together by shareholders in an effort to present useful, NON-HYPE information to anyone interested in this company. Please take a look at the site and formulate your own opinions about this possible investment. If you are not interested, please pardon the intrusion and good luck with your investment endeavors. Due to the initial volume at the site, the server may be busy, but please keep trying. member.aol.com dave tucker turbo17@yahoo.com

To: jeffrey rainey who wrote (7164)	9/8/1998 6:06:00 PM
From: Rob	Read Replies (1) \| Respond to of 8835

Response Biomedical (RBM.V) last $.85; shares issued approx 16 mill; FD approx 21 mill. - holds patented rights to science developed at UBC - platform technology allows quantitative point-of-care testing for analytes in any liquid - potential to perform approx 250 medical plus environmental and food tests using only one $1,000 reader. - Reliable results which are as sensitive and accurate as ELISA lab tests - its low cost ($1 cost to mfr a test strip and $1000 to mfr reader) in environment of health care cost pressures gives RAMP a significant competitive advantage over lab tests requiring costly equipment and multiple doctor visits - short and inexpensive development - 3 to 6 months per test - recent merchant banking agreement with Avenir to ensure financing through commercialization - experienced and respected management and board of directors - recent distribition and marketing partnerships with large biotechs (Beacon and BioCare) - production slated for end of 1998 with sales in early to mid 1999 - Looks like it should revolutionize healthcare I always recommend investors do their own DD as with any stock. Below are some sites to check out. I always recommend talking to company officials (and not just investor relations) before buying stock (604-681-4101). response-bio.com sedar.com devicelink.com There is also an SI site.